Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (231-240 of 306) with videos related to

Pageof 31
Sort By:
Journal of Gastroenterology|August 5, 2004
Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitisYoshiyuki Suzuki, Mariko Kobayashi, Tetsuya Hosaka, et al.
Drug Design, Development and Therapy|July 26, 2014
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavirFumitaka Suzuki, Hitomi Sezaki, Norio Akuta, et al.
Journal of Hepatology|June 5, 2012
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patientsAtsushi Ono, Fumitaka Suzuki, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 19, 2021
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavirFumitaka Suzuki, Hitomi Sezaki, Tetsuya Hosaka, et al.
Journal of Gastroenterology|October 5, 2016
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogsFumitaka Suzuki, Yoshiyuki Suzuki, Tetsuya Hosaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 11, 2012
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus loadYasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, et al.
Journal of Hepatology|April 25, 2008
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-upHiromi Yatsuji, Fumitaka Suzuki, Hitomi Sezaki, et al.
Journal of Gastroenterology|March 26, 2013
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis BMio Tanaka, Fumitaka Suzuki, Yuya Seko, et al.
Journal of Medical Virology|August 28, 2004
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudineMarie Matsuda, Fumitaka Suzuki, Yoshiyuki Suzuki, et al.
Internal Medicine (Tokyo, Japan)|June 4, 2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus loadYasuji Arase, Fumitaka Suzuki, Norio Akuta, et al.
Pageof 31

Showing results (231-240 of 306) with videos related to

Sort By:
Pageof 31
Journal of Gastroenterology|August 5, 2004
Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitisYoshiyuki Suzuki, Mariko Kobayashi, Tetsuya Hosaka, et al.
Drug Design, Development and Therapy|July 26, 2014
Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavirFumitaka Suzuki, Hitomi Sezaki, Norio Akuta, et al.
Journal of Hepatology|June 5, 2012
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patientsAtsushi Ono, Fumitaka Suzuki, Yusuke Kawamura, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 19, 2021
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavirFumitaka Suzuki, Hitomi Sezaki, Tetsuya Hosaka, et al.
Journal of Gastroenterology|October 5, 2016
Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogsFumitaka Suzuki, Yoshiyuki Suzuki, Tetsuya Hosaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 11, 2012
Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus loadYasuji Arase, Yoshiyuki Suzuki, Fumitaka Suzuki, et al.
Journal of Hepatology|April 25, 2008
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-upHiromi Yatsuji, Fumitaka Suzuki, Hitomi Sezaki, et al.
Journal of Gastroenterology|March 26, 2013
Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis BMio Tanaka, Fumitaka Suzuki, Yuya Seko, et al.
Journal of Medical Virology|August 28, 2004
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudineMarie Matsuda, Fumitaka Suzuki, Yoshiyuki Suzuki, et al.
Internal Medicine (Tokyo, Japan)|June 4, 2010
Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus loadYasuji Arase, Fumitaka Suzuki, Norio Akuta, et al.
Pageof 31